Experienced Management Team
Dr. Jeffrey Huth, MD. PhD, Founder and CEO
Dr. Jeffrey Huth, PhD. MD is the Founder and Chief Executive Officer of ScopiaRx, LLC. His work has focused on drug safety at both the research and clinical levels for 20 years. He received a BS in Chemistry from Xavier University in 1988, and a PhD in Pharmacology from the University of Michigan in 1993. From 1993-1997 he trained in protein biophysics at the National Institutes of Health in the laboratories of Dr. G. Marius Clore and Dr. Angela Gronenborn. Between 1997 and 2007, Dr. Huth was a senior scientist and group leader in the Advanced Technology Division of Pharmaceutical Discovery at Abbott Laboratories. There he invented ALARM NMR, which is a technology to predict adverse drug effects prior to costly animal and human studies. His work contributed to three drugs that advanced to clinical trials for rheumatology, oncology, and infectious disease indications. In 2011 he completed an MD degree at the University of Cincinnati College of Medicine, and in 2012, an internship in internal medicine at the University of Cincinnati Medical Center. He has authored over 40 publications in journals such as the Journal of the American Chemical Society, Cell, and the Proceedings of the National Academy of Sciences. Dr. Huth is a member of the American Chemical Society, the American Medical Association, Alpha Omega Alpha, and the American College of Physicians.
James J. McGraw Jr., JD., Chairman
James McGraw is Chairman of the Board of ScopiaRx, LLC. He is also a Corporate Partner at Keating Muething & Klekamp, and the President and Chief Executive Officer of KMK Consulting Company, LLC. His background is centered in business development, public utilities, insurance and non-profit organizations. His clients include national and international firms in the areas of real estate, financial services, healthcare, energy, manufacturing and technology. He has been actively involved in business and related client consulting for 36 years. Jim focuses on business formation and transactions, acquisitions and divestitures, along with a variety of related strategic work for clients which include corporate growth strategies, organizational design, leadership development, capital formation, public/private partnerships, performance benchmarking and strategic planning. Jim has been involved in numerous life science and healthcare companies, not-for-profits and economic development organizations as General Counsel and as a Board member. Jim has interacted with more than 3,000 CEOs and senior executives in the course of his work and has directed capital initiatives for clients totaling in excess of $500 million.
Allan Wallander, CFO
Al Wallander came to ScopiaRx in December 2010 with over 15 years of experience in high growth technology companies. He has management experience in financing, accounting, budgeting, board presentations, cash management, investments and strategic planning. Al also provides CFO services to other high growth/high potential organizations including Market6 and DotLoop. He has provided similar services to over 30 other early stage companies since 1997. Previously, Al was with U.S. Shoe Corporation as vice president – finance of footwear retail. Al started his career at Deloitte and earned his BS and MBA from Marquette University.
Dr. Larry Westfall, PharmD, COO
Dr. Westfall joined ScopiaRx in September 2016 with over 30 years of experience with pharmacy practice and the pharmaceutical industry. He has extensive management experience in health care quality initiatives and is a pioneer in bringing the practice of pharmacy into the value-based care model of health care. Dr. Westfall has held positions at Ortho-McNeil, where he was the director of quality management, and Johnson & Johnson where he was a director of healthcare quality alliances and the national director of strategic alliances.